Zemplar
Drug
AbbVie, Inc.
Total Payments
$86,333
Transactions
11
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $1,022 | 1 | 0 |
| 2017 | $85,311 | 10 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $83,333 | 9 | 96.5% |
| Space rental or facility fees (teaching hospital only) | $3,000 | 2 | 3.5% |
Payments by Type
Research
$83,333
9 transactions
General
$3,000
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| M10-149 | AbbVie, Inc. | $48,425 | 0 |
| M11-612 | AbbVie, Inc. | $34,658 | 0 |
| P12-053 | AbbVie, Inc. | $250.00 | 0 |
Top Doctors Receiving Payments for Zemplar
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Little Rock, AR | $86,333 | 11 |
Ad
Manufacturing Companies
- AbbVie, Inc. $86,333
Product Information
- Type Drug
- Total Payments $86,333
- Total Doctors 0
- Transactions 11
About Zemplar
Zemplar is a drug associated with $86,333 in payments to 0 healthcare providers, recorded across 11 transactions in the CMS Open Payments database. The primary manufacturer is AbbVie, Inc..
Payment data is available from 2017 to 2018. In 2018, $1,022 was paid across 1 transactions to 0 doctors.
The most common payment nature for Zemplar is "Unspecified" ($83,333, 96.5% of total).
Zemplar is associated with 3 research studies, including "M10-149" ($48,425).